A Phase 3, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Formulated in Multi-dose Vials Given With Routine Pediatric Vaccinations in Healthy Infants

Trial Profile

A Phase 3, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Formulated in Multi-dose Vials Given With Routine Pediatric Vaccinations in Healthy Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 Jul 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 29 Jan 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top